Notice 2020-15: High-deductible health plans, expenses related to coronavirus (COVID-19)
High-deductible health plans, coronavirus
The IRS today released an advance version of Notice 2020-15 as guidance allowing individual taxpayers with high-deductible health plans to receive testing and treatment related to the novel coronavirus (COVID-19) without jeopardizing the status of these health plans.
Notice 2020-15 [PDF 38 KB] provides guidance for individuals with a high-deductible health plan (HDHP) under section 223(c)(2)(A), and HDHPs that cover the cost of testing and treatment related to COVID-19. The notice also clarifies that an individual covered by the HDHP will not be disqualified from being an eligible individual under section 223(c)(1) who may make tax-favored contributions to a health savings account (HSA).
As further explained in a related IRS release—IR-2020-54—health plans that otherwise qualify as HDHPs will not lose that status merely because they cover the cost of testing for or treatment of COVID-19 before plan deductibles have been met. As the IRS noted, any vaccination costs continue to count as preventive care and can be paid for by an HDHP.
Today’s notice applies only to HSA-eligible high-deductible health plans. The IRS release directs employees and other taxpayers in any other type of health plan with questions about their own plan and its coverage to contact their health plan.
The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization. KPMG International Limited is a private English company limited by guarantee and does not provide services to clients. No member firm has any authority to obligate or bind KPMG International or any other member firm vis-à-vis third parties, nor does KPMG International have any such authority to obligate or bind any member firm. The information contained herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation. For more information, contact KPMG's Federal Tax Legislative and Regulatory Services Group at: + 1 202 533 4366, 1801 K Street NW, Washington, DC 20006.